In this video, an international panel of experts sat down with Oncology Learning Network to discuss the 3 Bruton’s tyrosine kinase (BTK) inhibitors active in the treatment of Waldenström macroglobulinemia (WM): ibrutinib, acalabrutinib, and zanubrutinib.

This discussion is moderated by Steven Treon, MD, PhD, Director of the Bing Center for Waldenström’s macroglobulinemia at the Dana-Farber Cancer Institute, and Professor of Medicine at Harvard Medical School, Boston, Massachusetts.

Dr Treon is joined by 3 international experts, Christian Buske, MD, Medical Director at the Comprehensive Cancer Center and the Institute of Experimental Cancer Research at the University Ulm, Germany; Marie Jose Kersten, MD, PhD, Professor of Medicine, Amsterdam University Medical Centers, Netherlands; and Prof Judith Trotman, MBChB, FRACP, FRCPA, Concord Cancer Center, Concord Repatriation General Hospital and the University of Sydney, Australia.

Watch Dr Treon, Dr Buske, Dr Kersten, and Prof Trotman explain the data behind each of these drugs, as well as factors a clinician may consider when choosing a BTK inhibitor for a patient, including availability, compliance, need for deeper IgM responses, efficacy, and toxicity.